Mark S Tichenor

发表

Preclinical Characterization of the FAAH Inhibitor JNJ-42165279.

Sandy J. Wilson, M. Karbarz, S. Chaplan, 2015, ACS medicinal chemistry letters.

The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors.

Sandy J. Wilson, M. Karbarz, S. Chaplan, 2016, Bioorganic & medicinal chemistry letters.

Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory Activity.

John J. M. Wiener, Jennifer D. Venable, Jianmei Wei, 2021, ACS medicinal chemistry letters.

Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.

Sandy J. Wilson, M. Karbarz, S. Chaplan, 2012, ACS medicinal chemistry letters.

Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer.

D. Boger, F. Shiga, Mark S Tichenor, 2006, Journal of the American Chemical Society.

Yatakemycin: total synthesis, DNA alkylation, and biological properties.

D. Boger, Mark S Tichenor, 2008, Natural product reports.

Systematic exploration of the structural features of yatakemycin impacting DNA alkylation and biological activity.

D. Boger, Karen S Macmillan, Mark S Tichenor, 2007, Journal of the American Chemical Society.

Asymmetric Total Synthesis of (+)- and ent-(-)-Yatakemycin (I) and Duocarmycin SA (II): Evaluation of Yatakemycin Key Partial Structures and Its Unnatural Enantiomer.

D. Boger, F. Shiga, Mark S Tichenor, 2007 .

Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.

D. Boger, Mark S Tichenor, David B. Kastrinsky, 2004, Journal of the American Chemical Society.

Yatakemycin: Total Synthesis, DNA Alkylation, and Biological Properties

D. Boger, Mark S Tichenor, 2008 .

Total Synthesis, Structure Revision, and Absolute Configuration of (+)‐Yatakemycin.

D. Boger, Mark S Tichenor, David B. Kastrinsky, 2004 .

Rational design, synthesis, and evaluation of key analogues of CC-1065 and the duocarmycins.

D. Boger, A. Zaid, P. Baraldi, 2007, Journal of the American Chemical Society.

Novel Reagent Space: Identifying Unorderable but Readily Synthesizable Building Blocks.

R. DesJarlais, D. M. Chung, T. Mirzadegan, 2021, ACS medicinal chemistry letters.

Ruthenium-mediated cycloaromatization of acyclic enediynes and dienynes at ambient temperature.

Mark S Tichenor, Seth J. Friese, J. O'connor, 2002, Journal of the American Chemical Society.

Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease.

W. Chai, Jennifer D. Venable, J. Edwards, 2020, Journal of medicinal chemistry.

Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

John J. M. Wiener, Jennifer D. Venable, Jianmei Wei, 2022, Journal of medicinal chemistry.

Rational design, synthesis, and evaluation of key analogues of CC-1065 and the duocarmycins.

D. Boger, A. Zaid, P. Baraldi, 2007, Journal of the American Chemical Society.

Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites.

M. Karbarz, S. Chaplan, N. Hawryluk, 2012, Bioorganic & medicinal chemistry letters.

Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.

M. Karbarz, S. Chaplan, J. Keith, 2012, ACS medicinal chemistry letters.

Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation

Jennifer D. Venable, Thomas B. Sundberg, M. Rives, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.

Jennifer D. Venable, R. Thurmond, B. Savall, 2015, Journal of medicinal chemistry.